- Home
- PHGE vs OSRH Comparison
PHGE vs OSRH Comparison
Compare PHGE & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- OSRH
- Stock Information
- Founded
- PHGE 2015
- OSRH N/A
- Country
- PHGE Israel
- OSRH United States
- Employees
- PHGE N/A
- OSRH N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- OSRH
- Sector
- PHGE Health Care
- OSRH
- Exchange
- PHGE Nasdaq
- OSRH Nasdaq
- Market Cap
- PHGE 12.6M
- OSRH 11.1M
- IPO Year
- PHGE N/A
- OSRH N/A
- Fundamental
- Price
- PHGE $0.48
- OSRH $0.74
- Analyst Decision
- PHGE Strong Buy
- OSRH
- Analyst Count
- PHGE 1
- OSRH 0
- Target Price
- PHGE $15.00
- OSRH N/A
- AVG Volume (30 Days)
- PHGE 389.8K
- OSRH 13.9M
- Earning Date
- PHGE 11-13-2025
- OSRH 08-14-2025
- Dividend Yield
- PHGE N/A
- OSRH N/A
- EPS Growth
- PHGE N/A
- OSRH N/A
- EPS
- PHGE N/A
- OSRH N/A
- Revenue
- PHGE N/A
- OSRH $104,735.00
- Revenue This Year
- PHGE N/A
- OSRH N/A
- Revenue Next Year
- PHGE N/A
- OSRH N/A
- P/E Ratio
- PHGE N/A
- OSRH N/A
- Revenue Growth
- PHGE N/A
- OSRH N/A
- 52 Week Low
- PHGE $0.34
- OSRH $0.45
- 52 Week High
- PHGE $1.16
- OSRH $13.40
- Technical
- Relative Strength Index (RSI)
- PHGE 50.36
- OSRH 53.32
- Support Level
- PHGE N/A
- OSRH $0.57
- Resistance Level
- PHGE $0.51
- OSRH $0.62
- Average True Range (ATR)
- PHGE 0.03
- OSRH 0.08
- MACD
- PHGE -0.03
- OSRH 0.02
- Stochastic Oscillator
- PHGE 85.12
- OSRH 47.43
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.